Grading System
Strength of
Recommendation
Quality of Evidence
1 = strong
⊕⊕⊕⊕ = high
⊕⊕⊕ = moderate
2 = weak
⊕⊕ = low
⊕ = very low
Abbreviations
apoB, apolipoprotein B; CI, confidence interval; CVD, cardiovascular disease; DHA,
docosahexaenoic acid; EPA, eicosapentaenoic acid; FCHL, familial combined hyperlipidemia;
FHA, familial hypoalphalipoproteinemia; FHTG, familial hypertriglyceridemia; HDL,
high-density lipoprotein; HMG CoA, hydroxymethylglutaryl coenzyme A; HTG,
hypertriglyceridemia; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein;
Lp(a), lipoprotein(a); LpL, lipoprotein lipase; NEFA, nonesterified fatty acid; VLDL, very low
density lipoprotein
Source
Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AFH.
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice
Guideline. J Clin Endocrinol Metab. 2012 Sep;97(9):2969-2989.
Disclaimer
This Guideline attempts to define principles of practice that should produce high-quality patient
care. It focuses on the needs of primary care practice, but also is applicable to providers at all levels.
This Guideline should not be considered exclusive of other methods of care reasonably directed
at obtaining the same results. The ultimate judgement concerning the propriety of any course of
conduct must be made by the clinician after consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated with
the distributor of this clinical reference tool.
HTG121202c
5740 Executive Drive Suite 218
Baltimore, MD 21228
TEL: 410-869-3332 • FAX: 410-744-2150
For additional copies: orders@GuidelineCentral.com
Copyright © 2013 All rights reserved
